Virtual Library
Start Your Search
SUMERYA Duru Birgi
Author of
-
+
EP1.08 - Oligometastatic NSCLC (ID 198)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Oligometastatic NSCLC
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.08-03 - Results of Definitive Treatment in Patients with Synchronous Oligometastatic Non Small Cell Lung Cancer (Now Available) (ID 2444)
08:00 - 18:00 | Author(s): SUMERYA Duru Birgi
- Abstract
Background
To evaluate the prognostic factors and outcome of both thoracic radiotherapy (RT) and oligometastasis treatment with curative intent in cases with oligometastatic non-small lung carcinoma (NSCLC).
Method
We retrospectively evaluated 18 synchronous oligometastatic NSCLC patients who underwent radical treatment in the thoracic and oligometastasis region between 2015 and 2018 in our center.
Result
The median age of patients was 62 years. Only two of 18 patients had ≥2 organ involvement. Patients' clinical and treatment characteristics are summarized in Table-1 and Table-2. Median follow-up was 7 months. The median overall survival (OS) was 11 months and the median progression-free survival (PS) was 8 months. The one year OS and PS was found 45% and 50% respectively. In the univariate analysis, the localization of oligometastasis (brain vs other distant met) was found as an effective factor on OS. The median survival was found to be 7 months in patients with brain metastasis whereas 18 months in patients with other metastasis. Although treatment type (RT vs surgery) or RT technique applied for oligometastasis (Conformal RT (3DCRT)/IMRT vs Stereotactic RT (SRS/SBRT)) did not cause significant difference on OS in univariate analysis; in the multivarian analysis, the localization of oligometastasis (HR: 7.3, 95% CI 1.33-40.5) and the RT technique applied for oligometastasis (HR: 8.45, 95% CI 1.43- 49.9) were found to be prognostic factors on OS (p = 0.012). In the univariate analysis induction chemotherapy (CT) and RT tecnique were statistically significant for PS, but this significance could not be demonstrated in multivarian cox regression analysis.
Table.1:Demographic characteristics of patients and the results in univarian analysis
Number (%) p value (OS) p value (PS) Age (years)
median (min-max)
<60 years
≥ 60 years61.5 (35.0-73.0)
7 (38.9)
11 (61.1)0.725 0.355 Gender
Male
Female16 (89.0)
2 (11.0)0.786 0.876 Histology
Adenocarcinoma
SCC12 (67.0)
6 (33.0)0.145
0.785 T stage
T1
T2
T3
T4
Unknown3(17.0)
4(22.0)
4(22.0)
6(33.0)
1(6.0)
0.87 0.369 N stage
No
N1
N2
N3
Unknown4(22.0)
5(28.0)
8(44,0)
0(0)
1(6.0)0.169 0.222 Table 2: Treatment characteristics of patients and the results in univarian analysis
Number (%) p value (OS) p value (PS) RT region
Brain
Bone
Surrenal
Liver
Other7 (50)
3 (21)
1 (7)
1 (7)
2 (15)0.299 0.021 Metastasis number
1
2
3-5
12 (66.0)
3 (17.0)
3 (17.0)0.393 0.794 Metastatic organ
Brain
Other
Bone
Surrenal
Liver
Multiple
Other7 (39.0)
11(61.0)
3 (17.0)
3 (17.0)
1 (5.0)
2 (11.0)
2 (11.0)
0.031 0.421 Oligometastasis treatment
Surgery
RT
Surgery and RT
4 (22.0)
10 (56.0)
4 (22.0)0.412 0.534 Oligometastasis RT tecnique
SRS/SBRT
1x20 Gy
5x5 Gy
3DCRT/IMRT
3x 10 Gy
3x 15 Gy4 (28.5)
3
1
10 (72.5)
6
40.065 0.468 Thoracic RT Dose
45
60
64-66
4 (22.0)
5 (28.0)
9 (50.0)0.194 0.536 Induction CT
Yes
No11(61.0)
7 (39.0)0.067 0.044 Concurrent CT
No
Yes
6 (33.0)
12 (67)
0.084 0.142
Results of treatment with thoracic RT and oligometastasis region in oligometastatic NSCLC seem promising. The localization of the oligometastasis and the technique of RT are important factors.
-
+
EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Treatment in the Real World - Support, Survivorship, Systems Research
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.16-07 - National, Observational, Multicentric Study in Stage III Non-Small Cell Lung Cancer Patients in Turkey: Stone Trial (Now Available) (ID 2570)
08:00 - 18:00 | Author(s): SUMERYA Duru Birgi
- Abstract
Background
In this national, non-interventional study, our aim is to collect stage III non-small cell lung cancer (NSCLC) data derived from medical records in nationwide to capture and consolidate information of treatment patterns, treatment effectiveness and patient outcomes in the real-world setting. This study was carried out with the collaboration of Turkish Society for Radiation Oncology.
Method
Patients newly diagnosed with primary stage III NSCLC between 01 January 2013 and 31 December 2017 included. A total of 556 patients from 10 hospitals in Turkey were included in this study. Patient characteristics, initial treatment modalities, chemotherapy regimens, overall (OS) and local progression free survival (LPFS), failure patterns and secondary treatments after recurrence for recurrent patients were analyzed.
Result
Median age was 63 years (range, 56-69 years). 488 patients (%87.8) were male and 68 patients (%12.2) were female. Histopathological type was adenocarcinoma in 197 patients (%35.4), squamous cell carcinoma in 291 patients (%52.3) and others (Large Cell Carcinoma, mixed and unknown) in 68 patients (%12.3). 385 patients (%69.2) received definitive/curative therapy, 23 patients (%4.1) received palliative, 33 patients (%5.9) received adjuvant and 63 patients (%11.3) received neoadjuvant oncological treatment. 54.8% of patients received concomitant chemoradiotherapy, 22.1% of patients received concomitant chemoradiotherapy+ adjuvant chemotherapy, 12.2% of patients received only radiotherapy and, 10.8% of patients received sequential chemotherapy followed by radiotherapy. 75 patients (13.4%) underwent curative resection as primary treatment and, 33 (5.9%) of them received adjuvant chemoradiotherapy and/or radiotherapy. The 2- and 3-year of OS were 57%, and %43, respectively. 2- and 3-year of PFS were %38 and %25, respectively.
Conclusion
To our best knowledge, this is the first national study representing valuable information about real-life data in stage III NSCLC population in Turkey.